GRAIL (GRAL) Stock Analysis

What GRAIL does

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Key metrics

ETFs linked to GRAL

Broad-market and Healthcare sector ETFs an investor holding GRAIL is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GRAL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for GRAIL?

GRAIL trades under the ticker GRAL on NASDAQ.

Which exchange is GRAL listed on?

GRAL is listed on NASDAQ.

What sector does GRAIL operate in?

GRAIL is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze GRAL in a portfolio?

PortView shows GRAL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.